C

Corvus Pharmaceuticals
D

CRVS

4.70000
USD
-0.06
(-1.16%)
مغلق
حجم التداول
20,137
الربح لكل سهم
-0
العائد الربحي
-
P/E
-5
حجم السوق
362,438,789
أصول ذات صلة
A
ALT
-0.02500
(-0.61%)
4.07500 USD
A
AYTU
-0.02500
(-0.95%)
2.62000 USD
MRNA
MRNA
0.125
(0.37%)
34.145 USD
N
NNVC
-0.02000
(-1.18%)
1.68000 USD
N
NVAX
-0.16500
(-2.16%)
7.47000 USD
R
RFL
-0.01900
(-0.89%)
2.11000 USD
V
VCEL
0.410
(1.03%)
40.160 USD
المزيد
الأخبار المقالات

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).